Haemophilia Treatment Market to Grow with a CAGR of 5.74% through 2030
Increasing prevalence of hemophilia and surging trend of prophylaxis
treatment is expected to drive the Global Haemophilia Treatment Market growth
in the forecast period, 2026-2030
According to TechSci Research report, “Haemophilia Treatment Market – Global Industry Size, Share, Trends, Competition, Forecast & Opportunities, 2030F”, Global Haemophilia Treatment Market was valued at USD 11.38 Billion in 2024 and is anticipated to reach USD 15.73 Billion with a CAGR of 5.74% through 2030. The increase in research and development studies focused on
treatment therapies, along with the growing target population and diagnosis
rate, are key factors driving the growth of the hemophilia treatment market.
Additionally, the rise in the use of prophylactic treatment for
hemophilia contributes to this growth. However, the high cost of hemophilia
treatment, limited availability of medicines, and serious adverse effects
associated with plasma-derived products are anticipated to hinder market
growth. On the other hand, the growing awareness about hemophilia in developing
countries presents an opportunity for the expansion of the hemophilia treatment
market.
One of the primary drivers of haemophilia market growth is the increasing prevalence of haemophilia, which is driving the demand for treatment options. Patients with severe haemophilia require frequent treatment to maintain sufficient clotting factors and prevent bleeding. According to the Centers for Disease Control and Prevention, Hemophilia A affects 1 in every 5,000 male births in the United States. As the number of dependent patients requiring comprehensive care continues to rise, this significant prevalence is expected to have a substantial impact on the market. Moreover, patients receiving quality care are more likely to have fewer co-morbidities and a reduced risk of severe bleeding. Thus, the increasing number of patients with haemophilia has led to a higher demand for haemophilia therapy, resulting in increased product adoption rates.
Browse over XX market data Figures spread through XX Pages and an
in-depth TOC on
"Global Haemophilia Treatment Market.”
The Global Haemophilia Treatment Market is segmented into type, product,
treatment, therapy, regional distribution, and company.
Based on the Therapy, Gene Therapy emerged as the dominant segment in the Global Haemophilia Treatment Market in 2024, revolutionizing the approach to managing this lifelong genetic disorder. Unlike traditional treatments that require frequent administration of clotting factor concentrates, gene therapy offers a potentially curative approach by addressing the root cause of hemophilia—defective or missing genes responsible for clotting factor production. This breakthrough innovation has gained significant traction due to its ability to provide long-lasting or even permanent benefits with a single treatment. The dominance of gene therapy is fueled by its proven efficacy in reducing bleeding episodes and minimizing or eliminating the need for regular clotting factor replacement. For instance, recent FDA-approved gene therapies for hemophilia A and B, such as Roctavian (valoctocogene roxaparvovec), have demonstrated substantial success in clinical trials, significantly improving patients' quality of life. The growing adoption of these therapies underscores their impact on the hemophilia treatment landscape.
Based on region, Asia-Pacific emerged as the fastest growing region in the Global Haemophilia Treatment Market during the forecast period. This is driven by a combination of increased awareness, improved healthcare infrastructure, and growing accessibility to advanced treatments. The region's significant population size includes a large number of undiagnosed and untreated hemophilia cases, creating substantial growth potential. Governments and healthcare organizations in countries like China, India, and Japan are intensifying efforts to enhance hemophilia care through awareness campaigns and policy support. For instance, initiatives like the World Federation of Hemophilia (WFH) outreach programs in Asia have improved diagnosis rates and access to treatment in underserved areas. The introduction of government-funded healthcare schemes has also played a critical role in expanding access to clotting factor therapies and non-factor treatments. Additionally, the increasing availability of recombinant therapies and extended half-life clotting factors has driven market growth, as these innovations offer more effective and convenient treatment options. The region is also experiencing growth in research and clinical trials for gene therapy and other advanced treatments. For example, Japan and South Korea are leading the way in biotech advancements, further boosting the market. These factors collectively position Asia-Pacific as a dynamic and rapidly expanding market for hemophilia treatment, meeting the growing demands of its patient population.
Major companies operating in Global Haemophilia Treatment Market
are:
- Bayer AG
- BioMarin
Pharmaceutical, Inc.
- CSL
Behring LLC
- Kedrion
S.p.A
- Novo
Nordisk A/S
- Pfizer,
Inc.
- Octapharma
AG
- Sanofi
S.A.
- Takeda
Pharmaceutical Company
- Grifols
SA
Download Free Sample Report
Customers can also request for 10% free customization on this report
“The growing number of hemophilic patients and the increasing prevalence
of genetic abnormalities worldwide are key factors that positively impact the
market. Moreover, the rising diagnosis rate of the disease and the growing
adoption of prophylactic treatment for hemophilia present profitable growth
opportunities for leading market players. Furthermore, government agencies in
various countries are organizing extensive awareness campaigns to promote early
diagnosis and appropriate screening procedures for neonates, thereby creating a
positive market outlook. Additionally, substantial investments in research and
development (R&D) activities are being made due to the limited availability
of treatment options. Notably, industry leaders are focused on introducing
advanced diagnostic tools and therapies to enhance the effectiveness and
precision of hemophilia treatment, further contributing to a favorable market
landscape. Additionally, significant investments are being made to expand the
establishment of specialized hemophilia treatment centers (HTCs) globally,
which is expected to drive market growth.,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Haemophilia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Haemophilia A, Haemophilia B, Haemophilia C), By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents), By Treatment (On-demand and Prophylaxis), By Therapy (Replacement Therapy, ITI therapy and Gene Therapy), By Region and Competition, 2020-2030F”, has evaluated the future growth potential
of Global Haemophilia Treatment Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Haemophilia Treatment Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com